Rapport Therapeutics, Inc. (RAPP) Stock Forecast
RAPP analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.94 / 5 from 16 analysts
- Price target
- $62.71 average of analyst targets
- Upside to target
- +127.4% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-1.21
- 52-week range
- $24.37 – $52.50
RAPP analyst ratings
16 analystsNumber of analysts at each rating.
RAPP price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RAPP earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.22 | −$1.36 | −$1.08 | −$0.71 | −72.0% | 12 |
| Current fiscal year (2026) | −$4.04 | −$4.51 | −$3.50 | −$2.86 | −41.2% | 12 |
| Next fiscal year (2027) | −$5.11 | −$6.80 | −$3.81 | −$4.04 | −26.5% | 12 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RAPP revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 14 |
| Current fiscal year (2026) | $20.1M | $20.0M | $21.0M | 0.0% | 16 |
| Next fiscal year (2027) | $0 | $0 | $0 | −100.0% | 15 |
RAPP EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RAPP revenue: reported and forecast
RAPP EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.01 | −$1.23 | −$1.23 | −$1.23 | −$1.22 | +21.5% | 0 up · 3 down |
| Current fiscal year (2026) | −$3.46 | −$4.09 | −$4.09 | −$4.09 | −$4.04 | +16.6% | 1 up · 0 down |
| Next fiscal year (2027) | −$4.40 | −$5.23 | −$5.23 | −$5.09 | −$5.11 | +16.2% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
RAPP earnings surprises
Reported EPS vs the consensus estimate for the last 10 quarters; RAPP beat in 6 of 10.
What analysts expect from RAPP
16 analysts cover Rapport Therapeutics; their consensus rating is strong buy (4.94 on a 1–5 scale, where 5 is a strong buy). The average price target is $62.71, 127.4% above the latest close of $27.57. Analysts expect earnings of −$4.04 per share for 2026, −41.2% from a year earlier. For 2027 the average estimate is −$5.11 per share. Rapport Therapeutics beat the EPS estimate in 6 of the last 10 quarters.
Related: RAPP income statement, RAPP key metrics, RAPP chart. See the RAPP stock overview for the latest quote and news.
RAPP forecast FAQ
What is Rapport Therapeutics's price target?
The average analyst price target for Rapport Therapeutics is $62.71, 127.4% above the latest close of $27.57.
Is Rapport Therapeutics a buy, hold or sell?
Of 16 analysts covering Rapport Therapeutics, 15 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Rapport Therapeutics's EPS forecast?
Analysts forecast −$4.04 per share for 2026 (range −$4.51 to −$3.50); for 2027 the estimate is −$5.11.
What is Rapport Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $20.1 million, growth of 0.0%.
When does Rapport Therapeutics report earnings?
Rapport Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-1.21.
Does Rapport Therapeutics usually beat earnings estimates?
Rapport Therapeutics reported EPS at or above the analyst estimate in 6 of the last 10 quarters.